



ABN 53 075 582 740

ASX ANNOUNCEMENT
18 November 2015

Chairman's Address

Bionomics Annual General Meeting 2015

Over the past several years, Bionomics has transitioned to a mature stage biotechnology company, with globally recognised core strengths in drug discovery and development, and multiple clinical candidates. I remind you of our mission to generate novel, best in class drug candidates which fill the needs of patients with Central Nervous System disorders and patients with cancer. It is therefore with great pleasure that I can report that 2015 has been another extremely positive year for the company as we aggressively move our drug pipeline forward.

Thus 2015 has seen Bionomics rapidly progress BNC210, moving this compound for the treatment of anxiety and depression into two clinical trials including a Phase 2 clinical trial in patients with Generalized Anxiety Disorder, underpinned by US\$10 million in non-dilutive funding from Silicon Valley Bank. We have also prepared BNC101, the first of our drug candidates targeting cancer stem cells, for clinical trial, highlighting our progress with this important asset from our 2012 acquisition of Biogen spin-out Eclipse Therapeutics.

We continue to focus on our two major partnerships with Merck & Co on programs targeting new treatments for pain and conditions such as ADHD, Alzheimer's disease, Schizophrenia and Parkinson's disease. Reflecting the importance of this relationship, and the solid progress made by our team, we were delighted to welcome Merck as a shareholder with their US\$9 million investment in Bionomics. Not only does this relationship represent significant validation of our ionX and MultiCore platform technologies, but we are also delighted that our annual Symposium with Merck continues to go from strength to strength, attracting cutting edge presentations from world renowned international and Australian researchers and clinicians – here in Adelaide.

In October 2014 Bionomics acquired the assets of Prestwick Chemical, a company which has played a crucial role in the development of our cognition and pain programs. The acquisition of Prestwick has enabled us to expand our MultiCore chemistry technology and strengthen our footprint in a key strategic market.

Bionomics remains in a strong cash position to progress its portfolio of promising drug candidates and to establish partnerships that will drive recurrent revenue into the future. We continue to attract high quality, sophisticated local and offshore institutional investors – attesting to the high regard with which Bionomics is held in global markets.

We remain focused on leveraging our proprietary platform technologies, with our business model of partnering compounds at carefully defined key value points aiming to manage our execution risk while at the same time building a revenue stream to fund our ongoing discovery programs. Having

the support and expertise of our strategic partners through our collaborations maximises the opportunity for our compounds to reach their target markets.

We are fortunate to have one of the most experienced and dedicated teams in the sector. Consistent with our expanded global operations, our strategic partnerships and our clinical stage development programs, this year we have been delighted to welcome Dr Jens Mikkelsen as our Chief Scientific Officer, Mr Jack Moschakis as our Legal Counsel & Company Secretary and Mr Tony Colasin as our Chief Business Officer. Tony is based at our US research facility in San Diego, whilst Jens, who has moved from Denmark to take up his appointment, and Jack are both based here in Adelaide.

I am excited by Bionomics' future and I acknowledge the support of all shareholders which has been so important for the Company. Thank you. Finally I'd like to thank my fellow Directors, our CEO & Managing Director Deborah Rathjen and the entire Bionomics team for their efforts during 2015.

I particularly wish to thank Dr Jonathan Lim, who retires from the Board at this meeting, for his outstanding contribution to the Company and wish him all the very best for the future. I also welcome Dr Alan Dunton to the Board – Alan brings significant technical, commercial and strategic expertise from his experience at the highest levels of the global pharmaceutical industry.

Let me now turn to Deborah Rathjen, your CEO and Managing Director, to provide you with a more comprehensive update after which we will invite questions, and then move to the formal part of the meeting.

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US

Stern IR, Inc.
Beth Del Giacco
+1 212 362 1200
beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 is expected to enter clinical trials in the fourth quarter of 2015. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This presentation contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.